Article
Cardiovascular safety of genetically proxied interleukin-5 inhibition: A mendelian randomization study.
Respiratory investigation - 1 Mar 2023
Alton Philip, Hughes David M, Zhao Sizheng Steven
Abstract excerpt
Interleukin-5 (IL-5) inhibitors have revolutionized the management of eosinophilic asthma. However, IL-5 is thought to play a protective role in atherosclerosis, and cardiovascular safety data for IL-5i are scarce. We used population-level data to examine the association between genetically proxied IL-5i and the risk of cardiovascular diseases. Genetic instruments for IL-5i were selected from a genome-wide...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
